The Product Specification File is the GMP master file maintained by the manufacturer for an investigational medicinal product. It consolidates the controlled reference documents that specify exactly how this investigational medicinal product is to be manufactured, tested, labelled, stored and supplied for a specific clinical trial. Because product knowledge and requirements may change during development, the file is continuously updated and traceably linked to earlier versions.
Function within the pharmaceutical quality system
The Product Specification File is a key element of the manufacturer’s pharmaceutical quality system. It does not merely make individual requirements available; it brings them together for the specific investigational medicinal product and trial set-up: specifications and analytical methods for starting materials, packaging materials, intermediate, bulk and finished product, manufacturing processes and in-process controls, as well as the approved label text.
In addition, there are trial-specific references. The Commission guideline lists, among other things, the relevant approvals and amendments to the clinical trial, the trial protocol and, where applicable, randomisation codes, technical agreements, stability planning and reports, as well as storage and transport conditions. In particular, documenting all manufacturing, packaging, labelling and testing sites in the supply chain prevents a batch decision from being based on incomplete information.
Before manufacture of the first batch begins, the applicable parts of the file must be available. Its content depends on the product and the development phase; an early dosage form therefore does not necessarily require the same level of documentation as a later one. Separate files limited to the respective activity may be maintained at different sites, provided that the required information and changes are accessible at the relevant manufacturing site.
Controlled content and change traceability
The file links development and manufacturing without replacing development results themselves. A new specification, an amended packaging instruction or an adjusted transport temperature must be identifiable in the corresponding version of the Product Specification File. In this way, the manufacturer documents not only the current target state, but also which earlier version an already manufactured batch was based on.
The file is of particular importance for the packaging of blinded investigational medicinal products. This is where the approved label design, randomisation code, packaging instruction and sampling plan come together. If these documents are stored separately but not referenced via the Product Specification File, the Qualified Person cannot later reliably verify the batch documentation against the version valid for that trial.
Nor does the technical agreement between sponsor and manufacturer become redundant simply because it is mentioned in the file. The agreement assigns responsibilities; the Product Specification File establishes the link between that agreement and the product and the trial. This is particularly relevant when manufacturing, labelling, release and logistics are distributed across multiple organisations.
Distinction from the Investigational Medicinal Product Dossier
The Product Specification File is not to be equated with the Investigational Medicinal Product Dossier. The Investigational Medicinal Product Dossier is the pharmaceutical part of the documentation submitted to the authority with the application for authorisation of the clinical trial. By contrast, the Product Specification File remains the manufacturer’s controlled working document, which also consolidates instructions, agreements, supply chain information and operational traceability.
The two documents must be consistent in content, but they have different audiences and functions. The Investigational Medicinal Product Dossier explains the quality status to be assessed by the authority. The Product Specification File provides manufacturing and batch certification with the current references that are relevant for execution. The glossary entry “investigational-medicinal-product-dossier” therefore does not describe the same file.
Relevance for clinical trials
In a trial, the Product Specification File becomes critical in particular when a substantial modification, a new set of labels or an additional packaging site affects ongoing supply. The batch documentation must then refer to the correct version of the specification, protocol and approval status. Without this assignment, a correctly analysed product and a compliant trial shipment can still diverge—for example, because an old randomisation code or an outdated transport requirement was used.
Full-service CROs such as Mediconomics support the coordination of change statuses between sponsor, manufacturer and trial sites, the alignment of protocol amendments with labelling and shipping documentation, and the compilation of information that must be maintained consistently in technical agreements and clinical documentation systems. This makes the Product Specification File usable as a linking reference for operational trial supply.
For document control, it is also crucial that the manufacturer does not merely collect files, but defines the validity of the relevant reference for the ongoing process step. The master file only gains its control function through this link to the specific product, site and trial status.
Frequently Asked Questions (FAQ)
Who maintains the Product Specification File?
The manufacturer is responsible within the framework of its pharmaceutical quality system. Where multiple sites are involved, each site requires access to the parts necessary for its activities and the changes implemented there.
Does the file also include randomisation codes?
Where applicable, it should include the randomisation codes or refer to them. For blinded packaging, it is crucial that their status and handling correspond to the packaging and labelling documentation.
Why does the Qualified Person need access to the file?
A batch’s suitability for certification and release is assessed on this basis. For this, the quality status, the clinical trial approvals and the intended supply chain must be visible together.
Regulatory References
- Detailed Commission guidelines C(2017) 8179 final, Section 2.1 – describe the content, availability and maintenance of the Product Specification File.
- Commission Delegated Regulation (EU) 2017/1569, Articles 2 and 8 – assigns the file to the GMP system and the retention of documentation.
- Regulation (EU) No 536/2014, Article 63 – provides the basis for GMP for investigational medicinal products.